The Synaptic Bases of Mental Diseases

Gliapharm completes a CHF 2 Million financing to advance its drug development program

GliaPharm SA has completed a CHF 2 million financing. The company is initially focusing on an orphan neurological disease caused by a deficiency in brain metabolism that affects more than 100’000 children around the world from an early age through Read more…

Two EPFL spin-offs reach the finals of an international competition

hello tomorrow

EPFL spinoffs Lumendo and GliaPharm are among 80 deep-tech startups from around the world that have qualified for the finals of the Hello Tomorrow Challenge in Paris tomorrow. The finalists will pitch their company to a jury of technology specialists Read more…

GliaPharm moves to Campus Biotech

gliapharm team

C. Finsterwald, A. Magistretti, P. Magistretti, S. Lengacher GliaPharm, tackling Stephen Hawking’s disease, moves to Campus Biotech, Geneva. There are approximately 800 people working in the Campus Biotech building, say its promoteurs. However, some floors of the Lemanic pole dedicated Read more…